Molecular profiling of the biphasic components of hepatic carcinosarcoma by the use of targeted next-generation sequencing.

Our findings indicate that HCS could have been of monoclonal origin, and that the diverse clonal evolution might be driven by special molecular alterations in each tumour component. Our results also identify multiple therapeutic targets of HCS, which are valuable for the personalised treatment of HCS.